Bing-He Xu (Binghe Xu)

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 23

Top Topics

End Stage Renal Disease

Prognostic Factors

Ejection Fraction

Top Venues

Thoracic cancer

International journal of cancer

Cancer medicine

Cancer communications (London, England)

This page only lists publications with an associated author ORCID identifier.

Publications

Yun Wu, Hongnan Mo, Hangcheng Xu, Yan Wang, Jiayu Wang, Zongbi Yi, Bing-He Xu
Impact of HER2-low expression on the efficacy of endocrine therapy with or without CDK4/6 inhibitor in HR-positive/HER2-negative metastatic breast cancer: A prospective study. Thoracic cancer 15 (12) (2024)
Yun Wu, Hongnan Mo, Hangcheng Xu, Yan Wang, Jiayu Wang, Zongbi Yi, Bing-He Xu
Impact of HER2-low expression on the efficacy of endocrine therapy with or without CDK4/6 inhibitor in HR-positive/HER2-negative metastatic breast cancer: A prospective study. Thoracic cancer (2024)
Yun Wu, Hongnan Mo, Hangcheng Xu, Yan Wang, Jiayu Wang, Zongbi Yi, Bing-He Xu
Impact of HER2-low expression on the efficacy of endocrine therapy with or without CDK4/6 inhibitor in HR-positive/HER2-negative metastatic breast cancer: A prospective study. Thoracic cancer 15 (12) (2024)
Yun Wu, Hongnan Mo, Hangcheng Xu, Yan Wang, Jiayu Wang, Zongbi Yi, Bing-He Xu
Impact of HER2-low expression on the efficacy of endocrine therapy with or without CDK4/6 inhibitor in HR-positive/HER2-negative metastatic breast cancer: A prospective study. Thoracic cancer 15 (12) (2024)
Yun Wu, Hongnan Mo, Hangcheng Xu, Yan Wang, Jiayu Wang, Zongbi Yi, Bing-He Xu
Impact of HER2-low expression on the efficacy of endocrine therapy with or without CDK4/6 inhibitor in HR-positive/HER2-negative metastatic breast cancer: A prospective study. Thoracic cancer 15 (12) (2024)
Mingxia Jiang, Bin Shao, Donggui Wan, Jiaxuan Liu, Maiyue He, Yue Chai, Die Sang, Jiayu Wang, Zongbi Yi, Ying Fan, Peng Yuan, Bing-He Xu, Qiao Li
Eribulin combined with antiangiogenic agents in women with HER2-negative metastatic breast cancer: a retrospective multicenter study. Therapeutic advances in medical oncology 15 (2023)
Jingtong Zhai, Yun Wu, Zongbi Yi, Virginia G Kaklamani, Bing-He Xu
Advances in medical treatment of breast cancer in 2022. Cancer innovation 2 (1) (2023)
Hangcheng Xu, Yi-Qun Han, Yun Wu, Yan Wang, Jiayu Wang, Bing-He Xu
Clinicopathological characteristics and prognosis of microinvasive breast cancer: A population-based analysis. Cancer medicine (2022)
Di Zhang, Jingtong Zhai, Lixi Li, Yun Wu, Fei Ma, Bing-He Xu
Prognostic Factors and a Model for Occult Breast Cancer: A Population-Based Cohort Study. Journal of clinical medicine 11 (22) (2022)
Yiqun Han, Yun Wu, Hangcheng Xu, Jiayu Wang, Bing-He Xu
The impact of hormone receptor on the clinical outcomes of HER2-positive breast cancer: a population-based study. International journal of clinical oncology 27 (4) (2022)
Binliang Liu, Zong-Bi Yi, Yanfang Guan, Quchang Ouyang, Chunxiao Li, Xiuwen Guan, Dan Lv, Lixi Li, Jingtong Zhai, Haili Qian, Bing-He Xu, Zongbi Yi, Yixin Zeng
Molecular landscape of TP53 mutations in breast cancer and their utility for predicting the response to HER-targeted therapy in HER2 amplification-positive and HER2 mutation-positive amplification-negative patients. Cancer medicine 11 (14) (2022)
Meng Xiu, Pin Zhang, Xiang Wang, Ying Fan, Qiao Li, Qing Li, Jiayu Wang, Lin Dong, Yang Luo, Peng Yuan, Zongbi Yi, Bing-He Xu
Survival outcomes for dose-dense paclitaxel plus carboplatin neoadjuvant vs standard adjuvant chemotherapy in stage II to III triple-negative breast cancer: A prospective cohort study with propensity-matched analysis. International journal of cancer 151 (4) (2022)
Fengzhu Guo, Zongbi Yi, Wenna Wang, Yi-Qun Han, Pei Yu, Su Zhang, Quchang Ouyang, Min Yan, Xiaojia Wang, Xichun Hu, Zefei Jiang, Tao Huang, Zhongsheng Tong, Shu-Sen Wang, Yongmei Yin, Hui Li, Runxiang Yang, Huawei Yang, Yuee Teng, Tao Sun, Li Cai, Hongyuan Li, Xi Chen, Jianjun He, Xinlan Liu, Shune Yang, Jinhu Fan, You Lin Qiao, Jiayu Wang, Bing-He Xu
Profile, treatment patterns, and influencing factors of anthracycline use in breast cancer patients in China: A nation-wide multicenter study. Cancer medicine 10 (19) (2021)
Yi-Qun Han, Jia-Yu Wang, Bing-He Xu
Tumor Microenvironment Subtypes and Immune-Related Signatures for the Prognosis of Breast Cancer. BioMed research international 2021 (2021)
Yi-Qun Han, Zong-Bi Yi, Pei Yu, Wen-Na Wang, Qu-Chang Ouyang, Min Yan, Xiao-Jia Wang, Xi-Chun Hu, Ze-Fei Jiang, Tao Huang, Zhong-Sheng Tong, Shu-Sen Wang, Yong-Mei Yin, Hui Li, Run-Xiang Yang, Hua-Wei Yang, Yue-E Teng, Tao Sun, Li Cai, Hong-Yuan Li, Xue-Nong Ouyang, Jian-Jun He, Xin-Lan Liu, Shun-E Yang, You-Lin Qiao, Jin-Hu Fan, Jia-Yu Wang, Bing-He Xu
Comparisons of Treatment for HER2-Positive Breast Cancer between Chinese and International Practice: A Nationwide Multicenter Epidemiological Study from China. Journal of oncology 2021 (2021)
Peng Yuan, Bing-He Xu
Clinical Utility of Eribulin Mesylate in the Treatment of Breast Cancer: A Chinese Perspective. Breast cancer (Dove Medical Press) 13 (2021)
Yimeng Chen, Yin Guan, Jiayu Wang, Zongbi Yi, Yang Luo, Shanshan Chen, Pin Zhang, Qing Li, Ruigang Cai, Qiao Li, Hongnan Mo, Bo Lan, Xuelian Chen, Weihong Zhao, Bing-He Xu, Ying Fan
Platinum-based chemotherapy in advanced triple-negative breast cancer: A multicenter real-world study in China. International journal of cancer 147 (12) (2020)
Zongbi Yi, Zongbi Yi, Guohua Rong, Yanfang Guan, Chunxiao Li, Bing-He Xu
Clinical spectrum and prognostic value of TP53 mutations in circulating tumor DNA from breast cancer patients in China. Cancer communications (London, England) 40 (6) (2020)
Guohua Rong, Zongbi Yi, Zongbi Yi, Yanfang Guan, Yaping Xu, Lifeng Li, Bing-He Xu
Mutational characteristics determined using circulating tumor DNA analysis in triple-negative breast cancer patients with distant metastasis. Cancer communications (London, England) 40 (12) (2020)
Zong-Bi Yi, Pei Yu, Su Zhang, Wen-Na Wang, Yi-Qun Han, Qu-Chang Ouyang, Min Yan, Xiao-Jia Wang, Xi-Chun Hu, Ze-Fei Jiang, Tao Huang, Zhong-Sheng Tong, Shu-Sen Wang, Yong-Mei Yin, Hui Li, Run-Xiang Yang, Hua-Wei Yang, Yue-E Teng, Tao Sun, Li Cai, Hong-Yuan Li, Xi Chen, Jian-Jun He, Xin-Lan Liu, Shun-E Yang, Jia-Yu Wang, Jin-Hu Fan, You-Lin Qiao, Bing-He Xu
Profile and outcome of receptor conversion in breast cancer metastases: a nation-wide multicenter epidemiological study. International journal of cancer 148 (3) (2020)
Zongbi Yi, Yanfang Guan, Zong-Bi Yi, Lianpeng Chang, Qiao Li, Shanshan Chen, Wenjie Zhu, Xiuwen Guan, Chunxiao Li, Haili Qian, Xuefeng Xia, Ling Yang, Jianjun Zhang, Hatim Husain, Zhongxing Liao, Andrew Futreal, Jian Huang, Xin Yi, Bing-He Xu
Assessing tumor heterogeneity using ctDNA to predict and monitor therapeutic response in metastatic breast cancer. International journal of cancer 146 (5) (2019)
Jiayu Wang, Yiqun Han, Xiuqing Shi, Qing Li, Pin Zhang, Peng Yuan, Fei Ma, Yang Luo, Ruigang Cai, Ying Fan, Shanshan Chen, Qiao Li, Bing-He Xu
Phase I safety and pharmacokinetic study of cipatinib, an original dual tyrosine kinase inhibitor. Thoracic cancer 9 (8) (2018)
Xiaoyu Zhai, Ruoxi Hong, Ying Fan, Peng Yuan, Jiayu Wang, Die Sang, Junlin Chen, Chunying Zhao, Kaiping Ou, Fei Ma, Bing-He Xu
Analysis of the activity and safety of weekly low-dose bevacizumab-based regimens in heavily pretreated patients with metastatic breast cancer. Thoracic cancer 9 (5) (2018)